Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer

Soley Bayraktar; Hongming Qiu; Diane Liu; Yu Shen; Angelica M. Gutierrez-Barrera; Banu K. Arun; Aysegul A. Sahin

JOURNAL

Biomarkers in Cancer

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer

Submit a Paper

Soley Bayraktar, Hongming Qiu, Diane Liu, Yu Shen, Angelica M. Gutierrez-Barrera, Banu K. Arun and Aysegul A. Sahin

Biomarkers in Cancer 2015:7 39-49

Original Research

Published on 18 Aug 2015

DOI: 10.4137/BIC.S29716

Further metadata provided in PDF

Download Article PDF

Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract and Sharing
Article Metrics
Discuss

Abstract

Background: Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with BRCA1/2 mutations, but the results are conflicting. The limited data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers. Therefore, we designed this study to compare the clinicopathological characteristics of peritumoral benign breast tissue in patients with and without deleterious BRCA mutations.

Methods: Women with breast cancer (BC) who were referred for genetic counseling and underwent BRCA genetic testing in 2010 and 2011 were included in the study.

Results: Of the six benign histological features analyzed in this study, only stromal fibrosis grade 2/3 was found to be statistically different, with more BRCA noncarriers having stromal fibrosis grade 2/3 than BRCA1/2 carriers (P = 0.04).

Conclusion: There is no significant association between mutation risk and the presence of benign histologic features of peritumoral breast parenchyma.

Downloads

PDF (3.56 MB PDF FORMAT)

RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation (BIBDESK, LATEX)

What Your Colleagues Say About Biomarkers in Cancer

Biomarkers in Cancer was prompt, focused and straight forward during the process. Guidance was available throughout the process. This has been one of the most enjoyable experiences in dealing with the staff of a journal publishing good quality science. It's amazing that one day you submit corrections and the next day you receive corrected proofs. And the process continues until you are completely satisfied. Amazing. The peer review process matched the standard of any international ...

Dr Faiz Nasim (Professor of Biochemistry, The Islamia University of Bahawalpur, Pakistan)

More Testimonials